Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1

Vasilis Karavasilis1,2, Vasiliki Malamou-Mitsi3, Evangelos Briassoulis*1, Elena Tsanou3, Evangelia Kitsou3, Haralambos Kalofonos4, George Fountzilas5, Theodore Fotsis6 and Nicholas Pavlidis1,7

Address: 1Medical Oncology Department, Ioannina University Hospital, Ioannina, Greece, 2Sarcoma Unit, Royal Marsden Hospital, London, UK, 3Department of Pathology, Ioannina University Hospital, Ioannina, Greece, 4Medical Oncology Department, Patras University Hospital, Rion, Greece, 5Medical Oncology Department, School of Medicine, Aristotle’s University of Thessaloniki, Greece, 6Laboratory of Biochemistry, School of Medicine, University of Ioannina, Ioannina, Greece and 7Biomedical Research Institute-Foundation for Research and Technology (BRI-FORTH), Ioannina, Greece

Email: Vasilis Karavasilis - vasilios.karavasilis@rmh.nhs.uk; Vasiliki Malamou-Mitsi - vmalamou@cc.uoi.gr; Evangelos Briassoulis* - ebriasou@otenet.gr; Elena Tsanou - etsanu@cc.uoi.gr; Evangelia Kitsou - ebriasou@cc.uoi.gr; Haralambos Kalofonos - kalofon@med.upatras.gr; George Fountzilas - fountzil@med.auth.gr; Theodore Fotsis - thfotsis@cc.uoi.gr; Nicholas Pavlidis - npavlid@cc.uoi.gr

* Corresponding author

Published: 03 March 2005

BMC Cancer 2005, 5:25 doi:10.1186/1471-2407-5-25

Received: 17 December 2004
Accepted: 03 March 2005

This article is available from: http://www.biomedcentral.com/1471-2407/5/25

© 2005 Karavasilis et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

**Background:** Cancer of unknown primary remains a malignancy of elusive biology and grim prognosis that lacks effective therapeutic options. We investigated angiogenesis in cancer of unknown primary to expand our knowledge on the biology of these tumors and identify potential therapeutic targets.

**Methods:** Paraffin embedded archival material from 81 patients diagnosed with CUP was used. Tumor histology was adenocarcinoma (77%), undifferentiated carcinoma (18%) and squamous cell carcinoma (5%). The tissue expression of CD34, VEGF and TSP-1 was assessed immunohistochemically by use of specific monoclonal antibodies and was analyzed against clinicopathological data.

**Results:** VEGF expression was detected in all cases and was strong in 83%. Stromal expression of TSP-1 was seen in 80% of cases and was strong in 20%. The expression of both proteins was not associated with any clinical or pathological parameters. Tumor MVD was higher in tumors classified as unfavorable compared to more favorable and was positively associated with VEGF and negatively with TSP-1.

**Conclusion:** Angiogenesis is very active and expression of VEGF is almost universal in cancers of unknown primary. These findings support the clinical investigation of VEGF targeted therapy in this clinical setting.
Background
Cancer of unknown primary (CUP) is a unique clinical entity that accounts for an approximately 3% of human cancers[1]. Patients with CUP present with metastases for which the site of origin cannot be identified at initial workup. Early dissemination, unpredictability of metastatic pattern and aggressiveness constitute fundamental characteristics of these tumors. Although the clinical characteristics of CUP have been established, little is known about the underlying biology of these tumors [2,3].

Angiogenesis, the formation of new vessels, is essential for tumor growth and the development of metastases. It evolves through a complex multifactor process that involves interaction of pro-angiogenic and anti-angiogenic signals from tumor, endothelial and stromal cells. The angiogenic activity is reflected in the development of novel microvessels in tumor tissue that is quantified by the intratumoral microvessel density (MVD). Among several molecules implicated, Vascular Endothelial Growth Factor (VEGF) and Thrombospondin-1 (TSP-1) appear to be most relevant. Much evidence indicates that VEGF is a key activator of angiogenesis[4,5] and TSP-1 a primary endogenous inhibitor of angiogenesis[6] Up to now, no useful prognostic factors have been established other than the classic pathologic and laboratory ones and immunohistochemical detection of various factors did not add prognostic value in CUP.[7,8] Moreover, investigation of the expression of crucial angiogenesis factors that can be therapeutically targeted is today of great interest for the oncologists who deal with CUP clinical research.[9]

We were prompted to investigate angiogenesis in unknown primary cancer in an attempt to enrich our understanding of the biology of these tumors. We studied by immunohistochemistry the tissue expression of VEGF and TSP-1 in CUP and correlated with MVD and clinicopathological parameters. In a recently published study vascular endothelial growth factor, and CD34, factors were not found to be of prognostic value in adenocarcinoma of unknown primary.[8]

Methods
A total of 81 patients diagnosed with CUP and treated in three University Medical Oncology Settings (Ioannina, Patras and AHEPA, Thessaloniki, Greece) between January 1997 and December 2002 were selected on the basis of availability of archival tumor tissues and accessibility to medical notes. Pathology diagnosis was reviewed by two pathologists blinded to written pathology report and representative paraffin blocks were selected for immunohistochemistry.

Table 1: Demographics.

| Characteristic       | No (%) |
|----------------------|--------|
| Patients             | 81     |
| Sex                  |        |
| Male                 | 39     | 48 |
| Female               | 42     | 52 |
| Age (Years)          |        |
| Median               | 66     |
| Range                | 37–84  |
| PS                   |        |
| Median               | 1      |
| Range                | 0–3    |
| Histology            |        |
| Adenocarcinoma       | 62     | 77 |
| Well- and moderately differentiated | 27 | 43 |
| Poorly differentiated | 35     | 57 |
| Undifferentated carcinoma | 15 | 18 |
| With neuroendocrine features | 5 | 33 |
| Other undifferentiated neoplasms | 11 | 67 |
| Squamous cell carcinoma | 4 | 5 |
| Metastatic sites at presentation |        |
| Liver and/or multiple visceral involvement | 17 | 21 |
| Lymph nodes          | 23     | 29 |
| Mediastinal-retroperitoneal | 17 | 74 |
| Axillary             | 2      | 9 |
| Cervical             | 4      | 17 |
| Peritoneal cavity    | 19     | 23 |
| Peritoneal adenocarcinomatosis in females | 14 | 74 |
| Malignant ascites and other site | 5 | 26 |
| Lung                 | 5      | 6 |
| Bones                | 5      | 6 |
| Brain                | 4      | 5 |
| Neuroendocrine tumors | 4   | 5 |
| Multiple             | 4      | 5 |

Table 2: CUP subsets and outcome.

| Subgroups          | (#)     | (%) |
|--------------------|---------|-----|
| Favorable          | 50      | 62  |
| Unfavorable        | 31      | 38  |
| Treatment          | (#)     | (%) |
| Chemotherapy       | 64      | 78  |
| Radiotherapy       | 4       | 6   |
| Median survival    | (months)|     |
| All cases          | 10.5    |     |
| favourable cases   | 11.5    |     |
| unfavorable cases  | 8.5     |     |

Subgroup definition
Eligible cases categorized into unfavorable and more favorable subgroups (tables 1 and 2). Patients with poorly differentiated carcinoma with midline distribution, papillary adenocarcinoma of peritoneal cavity and
adenocarcinoma involving only axillary lymph nodes in women, squamous cell carcinoma involving cervical lymph nodes and poorly differentiated neuroendocrine carcinomas were assigned to favorable CUP subsets. Patients with adenocarcinoma metastatic to the liver, multiple visceral involvement and extensive metastatic bone disease were considered as unfavorable.

Systemic chemotherapy was given in 64 patients (78%); four patients with cerebral metastases received whole brain irradiation. Chemotherapy was consisted of a platinum based combination. Objective response to chemotherapy was observed in 34 patients (53%) while one patient with brain metastases responded to radiotherapy. Median survival for all patients was 10.5 months (Figure 1). Patients belonging to favorable subsets had a significantly higher response rate to treatment (Fisher’s t-test, $p = 0.04$) and a longer survival, 11.5 vs 8.5 months ($p = 0.01$).

**Immunohistochemistry**

Immunostaining was performed on formalin-fixed, paraffin-embedded tissue sections by the labeled streptavidin avidin biotin (LSAB) method. In brief, tissue sections were deparaffinised in xylene and dehydrated. They were immersed in citrate buffer (0.1 m, pH 0.6) and subjected to microwave twice for 15 min. Subsequently, all sections were treated for 30 min with 0.3% hydrogen peroxide in methanol to quench endogenous peroxidase activity. Mouse monoclonal antibodies directed against human CD34 antigen (M 7165, Dako) in dilution 1/50 $\beta$ VEGF Ab-3 (isoform 121, clone Jh121, Neomarkers) in dilution 1/50 and c) thrombospondin (Mob 315, DBS) in dilution1/50 were used. Positive control slides were included in all cases. All dilutions were made in TBS-1% BSA solution and were followed by overnight incubation.

The assessment of immunostaining was made by two experienced pathologists using light microscope. Tumor specimens too small to provide sufficient sections for all the immunoassaying procedures were disregarded from the study.

**Immunostaining evaluation**

Staining of endothelial cells for CD34 was used to evaluate the MVD. Any CD34 positive endothelial cell clusters clearly separated from each other were considered as single countable microvessels. A lumen was not required to identify a vessel. Larger vessels with muscular walls were excluded from counting. In each sample three areas of most prominent vascular density (hot spots) were identified at ×40 power field and microvessel counting was done under ×400 magnification. Counting was performed

---

**Figure 1**

Survival curve of 81 CUP patients analyzed

---

**Table 3: Assessment of tissue expression of VEGF, TSP-1 and CD34.**

| Immunostaining score | VEGF | TSP-1 | MVD (CD34) |
|----------------------|------|-------|------------|
| Median (range)       | 5    | 2     | 59 microvessels/mm² |
|                      | 2–6  | 0–3   | 16–300     |

| Expression intensity (% of cases) |       |       |
|-----------------------------------|-------|-------|
| Negative                          | 0     | 20    |
| Weak                              | 0     | 30    |
| Intermediate                      | 17    | 30    |
| Strong                            | 83    | 20    |
by two independent observers blinded to clinical information. The median count was used to make distinction between low and high MVD.

Immunoreactivity for VEGF was observed in stromal and epithelial cells. Only staining of tumor cells was considered for analysis. To evaluate the expression of VEGF protein, we devised a combined score that corresponds to the sum of staining intensity (0 = negative, 1 = weak, 2 = intermediate, 3 = strong staining) and percentile quadrants of positive cells (0 = 0%, 1 = 1–25%, 2 = 26–50%, 3 = >50%). The maximum score was 6. Score 2 was regarded to represent weak expression, score 3 intermediate and score 4–6 strong expression.

Staining for TSP-1 was only considered in regard to extracellular matrix. The expression of TSP-1 was characterized according to the extent and the intensity of staining classified as negative, +1: mild, focal, +2: intermediate, multifocal, +3: strong, diffuse reactivity.

Statistics
Staining results were analyzed against clinical subgroup, histological differentiation, response to treatment and survival. The association between MVD and clinical subgroup, histological differentiation and response to treatment was assessed by an unpaired t test. A Fisher’s exact test was used to determine associations between VEGF and TSP-1 and the clinical subgroup, histological differentiation and response to treatment. Spearman non parametric correlation test was used for associations between MVD, VEGF and TSP-1.

Survival was calculated by Kaplan-Meier method and comparison of survival curves was performed by the log rank test. For statistical significance a two-tailed p value was considered. The Graphpad Instat version 3.05 (Graphpad Software, Inc, San Diego, CA) and Prism version 4 (Graphpad Software, Inc, San Diego, CA) software programs were used for statistical analysis and graphing.

Results
Demographics of studied cases are depicted in Tables 1 and 2. Overall survival of patients included in this study is shown in Figure 1. (Median survival 10 months).

Immunohistochemistry
Microvessel density
Widespread staining for CD34 was seen in all tumor specimens. Within the most prominent vascular areas of the tumors the recorded mean MVD was 59 microvessels/mm² (range, 16 to 300 microvessels/mm²) (Table 3, figure 2). A positive association was observed between VEGF expression and MVD (Spearman r = 0.36, p = 0.0016) and negative with TSP-1.
VEGF expression
Positive staining of tumor cells for VEGF, both membranous and cytoplasmic was observed in all cases. This was strong in 83% of the cases and moderate in 17%. VEGF staining was heterogeneous within tumors comprising of areas of intense and also weak staining and demonstrated a characteristic granular cytoplasmic staining pattern. (Figure 3) A weak and focal positive reaction of intervening stromal cells (fibroblasts or/and macrophage) and endothelial cells was also seen in some cases. This staining was excluded from VEGF analysis. (Table 3)

TSP-1 expression
Stromal TSP-1 staining was detected in 80% of the cases, while in 20% it was absent (figure 4). Strong (score = 3)and intermediate (score = 2) TSP-1 staining was observed in 50% of cases and weak (score = 1) in 30% (Table 3). A negative association was observed between TSP-1 expression and MVD, (Spearman r = -0.3426, p = 0.003) while there was no association between TSP-1 and VEGF expression.

Association between immunostaining and clinicopathological variables
MVD was found statistically higher in unfavorable CUP cases compared to more favorable ones (70 vs 46 microvessels/mm2, t test, p = 0.034) (table 4). This was the only correlation detected between angiogenesis related tissue markers studied and clinicopathological variables. No association was detected between VEGF and TSP-1 and tumor differentiation, response to treatment, clinical subgroups and survival (Table 4).

Discussion
The investigation of the biological profile of CUP and the understanding of molecular pathways underlining these tumors has been limited. We have worked on these issues and found several oncoproteins overexpressed, but failed to establish any clinically relevant correlations[10,11]. We now investigated neo-angiogenesis by assessing MVD and the tissue expression of two representative molecules involved in angiogenesis; the major stimulator of angiogenesis VEGF (A), and the intrinsic angiogenic inhibitor TSP-1. Overall, we demonstrated that a high angiogenic activity occurs in CUP tumors, which is higher in unfavorable when compared with more favorable subsets.

VEGF is known to play a key role and MVD is considered to reflect the final result of the tumor angiogenesis cascade. In the present study, all cases were found to be VEGF-positive and in the majority VEGF was overexpressed. Tumor VEGF and MVD were strongly correlated that is in line with findings in solid tumors[12,13]. We failed to demonstrate any significant correlations of angiogenic activity with regard to clinical outcome, but this was obviously due to universal expression of both CD34 and VEGF in our cases.

We also demonstrated that in our series TSP-1 was overexpressed in 50% and was absent or weak in approximately half of the cases. TSP-1 correlated inversely with microvessel counts. The role of TSP-1 in epithelial tumor growth and metastases remains controversial. In vitro studies suggest that TSP-1 may promote tumor cell adhesion and invasion by up-regulating urokinase plasminogen activator and its receptor[14] but in clinical studies overexpression has been associated with a lower MVD score and a better clinical outcome in several carcinomas[15]. Moreover, other studies suggest that TSP-1 inhibits tumor progression and may serve as an indicator of less aggressive potential and of favorable prognosis in solid tumors[16]. We consider that low TSP-1 in our material reflects a suppression of anti-angiogenic mechanism of TSP-1 that possibly contributes to the aggressiveness of these tumors.

CUP patients have in general a brief life expectancy with a median survival approximately of 3–9 months.[17,18] It must be emphasized that CUP diagnosis applies to a heterogeneous group of patients who are usually grouped together in biological and therapeutic studies to obtain statistically meaningful results. However several patients fare better and enjoy longer survival and within this more favorable prognostic subgroup, unique subsets, such us young patients with midline tumors and women with peritoneal carcinomatosis or isolated axillary adenocarcinoma.
Table 4: Immunohistochemical expression of CD34 (MVD), VEGF, and TSP-1 and correlations.

| Variable          | MVD (counts) | VEGF (%) | TSP-1 (%) |
|-------------------|--------------|----------|-----------|
|                   | Median CD 34 | P value  | Low (<4)  | High (≥4) | P value | Low (<2) | High (≥2) | P value |
| Age               |              |          |           |           |         |          |           |         |
| < 65              | 62           | ns       | 20        | 80        | 35      | 27       |           |         |
| ≥ 65              | 58           |          | 15        | 85        | 22      | 16       |           |         |
| Tumor differentiation |              |          |           |           |         |          |           |         |
| Moderate and well |              |          | 3         | 28        |         | 12       | 20        |         |
| Poorly and undifferentiated | 59 | 14      | 3         | 55        | 32     | 36       |           |         |
| Clinical subgroups |              |          | ns        |           |         |          |           |         |
| More favorable    | 46           | 0.034    | 6         | 46        |         | 28       | 23        |         |
| Unfavorable       | 70           |          | 11        | 37        |         | 22       | 27        |         |
| Treatment outcome |              |          |           |           |         |          |           |         |
| Objective response| 58           | ns       | 11        | 39        |         | 22       | 28        |         |
| No response       | 59           |          | 4         | 46        |         | 25       | 25        |         |

Conclusion
In conclusion, we found that angiogenesis is very active and VEGF expression is universal in cancer of unknown primary, which supports the clinical investigation of VEGF targeted therapy in this clinical setting. To identify additional druggable molecular targets in cancer of unknown primary we need to advance our knowledge on the biology of these tumors and validate novel molecular therapeutics.

Competing interests
The author(s) declare that they have no competing interests.

Authors’ contributions
NP conceived, coordinated and designed the study, interpreted the data and drafted the manuscript; VK, EB, designed and carried out the study, performed the statistical analysis, interpreted the data and drafted the manuscript; VMM carried out the pathological and immunohistochemical study, interpreted data and drafted the manuscript; ET, EK carried out the pathological and immunohistochemical study, interpreted data and drafted the manuscript; HK, GF, TF participated in designing the study, acquisition and interpretation of data and revising critically the manuscript. All of the authors have read and approved the final manuscript.

References
1. Briasoulis E, Pavlidis N: Cancer of Unknown Primary Origin. Oncologist 1997, 2:142-157.
2. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA: Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003, 39:1990-2005.
3. van de Wouw AJ, Jansen RL, Speel EJ, Hillen HF: The unknown biology of the unknown primary tumour: a literature review. Ann Oncol 2003, 14:191-196.
4. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
5. Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002, 2:795-803.
6. Iruela-Arispe ML, Luque A, Lee N: Thrombospondin modules and angiogenesis. Int J Biochem Cell Biol 2004, 36:1070-1078.
7. Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, Merrouche Y, Laplanche A, Fizzari K: Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002, 20:4679-4683.
8. van de Wouw AJ, Jansen RL, Griffioen AW, Hillen HF: Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. Anticancer Res 2004, 24:297-301.
9. Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3:391-400.
10. Briasoulis E, Tsokos M, Fountzilas G, Bafaloukos D, Kosmidis P, Samantas E, Skarlos D, Nicolides C, Pavlidis N: Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group Study. Anticancer Res 1999, 18:1907-1914.
11. Pavlidis N, Briasoulis E, Bai M, Fountzilas G, Aagnostis N: Overexpression of c-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin. Anticancer Res 1995, 15:2563-2567.
12. Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Algar V, Kaufman S, Hallam S, Bicknell R, Walker JJ, Cairnduff F, Selby PJ, Perren TJ, Lansdown M, Banks RE: Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvesSEL density and effects of tamoxifen. Cancer Res 2000, 60:2898-2905.
13. Mattern J, Koomagi R, Volm M: Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996, 73:931-934.

14. Albo D, Rothman VL, Roberts DD, Tuszynski GP: Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor. Br J Cancer 2000, 83:298-306.

15. Kodama J, Hashimoto I, Seki N, Hongo A, Yoshinouchi M, Oikeda H, Kudo T: Thrombospondin-1 and -2 messenger RNA expression in invasive cervical cancer: correlation with angiogenesis and prognosis. Clin Cancer Res 2001, 7:2826-2831.

16. Grossfeld GD, Ginsberg DA, Stein JP, Bochner BH, Eshrig D, Groshek S, Dunn M, Nichols PW, Taylor CR, Skinner DG, Cote RJ: Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997, 89:219-227.

17. Levi F, Te VC, Erler J, Randimbison L, La Vecchia C: Epidemiology of unknown primary tumours. Eur J Cancer 2002, 38:1810-1812.

18. van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF: Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer 2002, 38:409-413.

19. Hess KR, Abdurrazzak MC, Leoni R, Raber MN, Abdurrazzak JL: Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 1999, 5:3403-3410.

20. Greco FA, Vaughn WK, Hainsworth JD: Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Intern Med 1986, 104:547-553.

21. Pavlidis N, Kosmidis P, Skarlos D, Briassoulis E, Beer M, Theoharis D, Bafaloukos D, Maravayas A, Fountzilas G: Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site. A Hellenic Cooperative Oncology Group Study. Ann Oncol 1992, 3:631-634.

22. Strnad CM, Grosh WW, Baxter J, Burnett LS, Jones H, Greco FA, Hainsworth JD: Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. Ann Intern Med 1989, 111:213-217.

23. Blanchard DK, Farley DR: Retrospective Study of Women Presenting with Axillary Metastases from Occult Breast Carcinoma. World J Surg 2004, 28:535-539.

24. Abdurrazzak JL, Abdurrazzak MC, Hess KR, Raber MN, Leoni R, Frost P: Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994, 12:1272-1280.

25. Hillen HF, Hak LE, Joosten-Achjanie SR, Arends JW: Microvessel density in unknown primary tumors. Int J Cancer 1997, 74:81-85.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2407/5/25/prepub